Journal article

Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin

CJ Yates, S Fourlanos, PG Colman, SJ Cohney

Transplantation | Published : 2013

Abstract

Background: The sensitivity of fasting plasma glucose (FPG) in screening for new-onset diabetes after transplantation (NODAT) has been questioned, particularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7 to 8 hr after administration. Oral glucose tolerance testing (OGTT) has been mooted as an alternative but is inconvenient for patients. Methods: We compared sensitivity of screening tests for NODAT at 6 weeks, 3 months, and 12 months after kidney transplantation in recipients receiving prednisolone, mycophenolate, and tacrolimus. Results: At 6 weeks, NODAT (capillary blood glucose [CapBG] ≥11.1 mmol/L, FPG ≥7.0 mmol/L, 2-hr plasma glucose ≥11.1 mmol/L, o..

View full abstract

Grants

Funding Acknowledgements

C.J.Y. has received project grants from Novo Nordisk and Australian Society of Nephrology-AMGEN for this work. S. F. and P. G. C. have no disclosures relevant to this publication. S.J.C. has no disclosures relevant to this publication but has received unrestricted educational grants from Novartis, Astellas, AMGEN, and Roche as well as conference travel support from Roche, Astellas, and Novartis.